Phase 3 open-label JNJ-77242113 in generalized pustular psoriasis and erythrodermic psoriasis

Phase 3, open-label, single-arm trial of icotrokinra in generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP), sponsored by Janssen Pharmaceutical. Primary endpoints: Percentage of participants with generalized pustular psoriasis who experience treatment success based on Clinical Global Impression scale according to Japanese Dermatological Association total score… and Percentage of participants with erythrodermic psoriasis who experience treatment success based on Clinical Global Impression scale at Week 16. Started Mar 2024; status: active, not recruiting.